NFKB1 and cancer: Moreover, because activation of the NF-κB pathway is implicated in resistance to taxanes and platinum-based drugs in several preclinical models of cancer [58], it is tempting to speculate that ERK5 inhibition might prevent NF-κB-mediated resistance to chemotherapy in EC cells.